INTRODUCTION
Somatostatin, a tetradecapeptide first isolated from ovine (1) and porcine (2) been detected in extracts of the pancreas and gastrointestinal tract of several species (3) (4) (5) , and localized to D-cells in the fundic and antral regions of the stomach (6) and in the islets of Langerhans (7) (8) (9) (10) (11) .
The release of somatostatin-like immunoreactivity (SLI)' from the isolated perfused dog pancreas and from isolated rat islets is stimulated by glucose (12, 15) , amino acids (13) (14) (15) and gut hormones (15) (16) (17) . SLI has been detected in the plasma of rats, dogs, and humans (18) (19) (20) , and rises in the peripheral venous plasma of dogs after the ingestion of a fat-protein meal (21) . It is likely that the post-prandial rise in peripheral plasma SLI levels is derived largely from the pancreas and stomach (21) . Although the foregoing observations are compatible with some type of physiologic role for somatostatin, the evidence that SLI in plasma resembles biologically active true somatostatin is limited (22) . The present study was, therefore, designed to characterize circulating SLI in plasma and to compare it with synthetic hypothalamic somatostatin with respect to certain physicochemical and immunologic properties.
METHODS
Plasma samples. It has been shown that intragastric administration of HCI elicits a rise in pancreaticoduodenal and antral vein SLI and that intraduodenal HC1 causes a rise in fundic vein SLI as well (21) . Blood samples (30 ml) were obtained from the pancreaticoduodenal and gastroepiploic (antral) veins of dogs during laparotomy after stimulation of SLI release by intragastric administration of 0.1 N HCI and from the short gastric vein (fundic) after the intraduodenal administration of 0.1 N HC1. They were collected in chilled tubes containing 1,000 kallikrein inhibitor units of aprotinin (Trasylol, Delbay Pharmaceuticals, Div. of Schering Corp., Bloomfield, N. J.) and 1.2 mg of EDTA per ml of whole blood IAbbreviation used in this paper: SLI, somatostatin-like immunoreactivity. (23) , using a nonrecirculating system and a semi-synthetic perfusion buffer as described elsewhere (13) . The plasma-free effluent from the pancreas was collected during perfusion with somatostatin secretagogues, arginine (15) , vasoactive intestinal peptide (17) , and cholecystokinin-pancreozymin (16 to a column (10 x 1 cm) of immobilized antibodies at a flow rate of 0.5 ml/min. Nonspecifically bound material was removed from the affinity columns by irrigation with 1 M NaCl adjusted to pH 10.4 with ammonia solution (sp gr 0.88), and the SLI bound specifically to the immobilized antibodies was eluted with 1 M formic acid solution.
Gel filtration. Gel filtration was carried out on 60 x 2.5-cm columns of Biogel P-10 (Bio-Rad Laboratories, Richmond, Calif.) and on 110 x 1.0-cm columns of Sephadex G-200, using 0.1 M NH4HCO3 buffer (pH 8.8) for elution, and on 60 x 2.5-cm columns of Sephadex G-25, using 2 M CH3COOH (pH 2.5) for elution. The columns were calibrated with markers of known molecular weight, blue dextran (Ml), human immunoglobulin-G (Ig) (M2), and synthetic somatostatin (M3).
Isoelectric focusing. Isoelectric focusing was carried out at 4°C in a LKB model 8100 column (LKB Instruments, Inc., Rockville, Md.) (110 ml) using LKB ampholines in the pH range of 7-11 (26) . Cytochrome c was employed to provide visual indication of completion of focusing. pH measurements were made using a Beckman Model 3550 pH meter (Beckman Instruments Corp., Fullerton, Calif.).
Thin layer chromatography. Thin layer chromatography of SLI samples, isolated by affinity chromatography, was carried out on cellulose plates (20 x 20 cm) using 1-butanol: pyridine:acetic acid: water (15:10:3:12) (vol/vol) for elution (2) . After chromatography, the plates were cut into 0.5-cm strips and each strip was incubated overnight in 0.2 M glycine containing 1% (wtlvol) human serum albumin (2 ml). SLI in the supernate was detected by radioimmunoassay.
Radioimmunoassay. SLI was measured by the radioimmunoassay procedure of Arimura et al. (19) , as modified by Harris et al. (20) , using Arimura antisomatostatin serum R101 which is directed against residues in the 5-11 region of the somatostatin molecule (25) .
RESULTS
Comparison of molecular size of endogenous SLI and synthetic somatostatin in plasma. At (Fig. 1B) . However, with the addition of larger amounts of synthetic somatostatin (100 ng/ml) to plasma, the SLI was eluted as two peaks, one in the 150,000-200,000-mol wt zone and one in the low molecular weight zone (Fig. IC) Fig. 1C indicates that the levels of immunoreactivity were >600 pg/ml. plasma was eluted from Sephadex G-25 columns in the same position as synthetic somatostatin in the absence of plasma (Fig. 2) . The minor peak of immunoreactivity observed in both chromatographs in the 3,000-mol wt zone may be indicative of a tendency of somatostatin to dimerize. To determine if the endogenous SLI was released from the pancreas as a 1,500-2,000-dalton polypeptide, plasma-free perfusate was collected from the effluent of the isolated pancreas during perfusion with D-cell secretagogues and subjected to gel filtration. At pH 8.8 all of the SLI of the plasma-free perfusate appeared in the 1,600-dalton zone of Biogel P-10 columns (Fig. 3A) . However, when plasma containing the D-cell secretagogue arginine (10 mM) was perfused through the pancreas, all of the secreted SLI was eluted at pH 8.8 in the void volume of these columns (Fig. 3B) . These results suggest that both endogenous SLI and synthetic somatostatin are bound to a high molecular weight component of canine plasma. When the pancreas was perfused with plasma containing the more powerful D-cell secretagogue, cholecystokininpancreozymin (0.075 Ivy U/ml), however, the secreted SLI appeared in both the high and low molecular weight zones (Fig. 3C) ELUTION VOLUME (ml) 280 FIGURE 3 Elution profiles of (A) -1,000 pg/ml endogenous SLI from the isolated pancreas perfused with plasma-free buffer solution, (B) -500 pg/ml endogenous SLI from the isolated pancreas perfused with plasma containing arginine, and (C) -1,500 pg/ml endogenous SLI from the isolated pancreas perfused with plasma containing cholecystokininpancreozymin on Biogel P-10 columns at pH 8.8.
binds to the large molecular weight plasma components, the NH2-terminally modified analogue of somatostatin, 1251-labeled Tyr1-somatostatin, and the analogue, 1251-labeled Tyr1 -somatostatin, modified close to the COOH-terminal, were added to plasma and incubated at 5°C overnight. At pH 8.8 the NH2-terminally modified analogue was eluted in the 1,500-2,000-dalton zone, but the COOH-terminally modified analogue, 1251-labeled Tyr'1-somatostatin, was eluted in the 150,000-200,000-dalton zone. The region of the somatostatin molecule that binds to the plasma component was further investigated by means of affinity chromatography with both S-27 antiserum (directed against the central portion ofthe somatostatin molecule) and antiserum S-81 (directed against the NH2-terminal region). Affinity chromatography of plasma samples on a column of immobilized antibodies from S-27 removed -90% of endogenous SLI from plasma collected from the pancreatic and gastric veins and of synthetic somatostatin added to plasma (Fig.  4) , whereas chromatography of plasma samples on immobilized antibodies from antiserum S-81 removed neither (Fig. 5) . However, when they were in a plasma- [29] .) The SLI removed from various plasma samples and from perfusate by the S-27 column was recovered by irrigation with 1 M formic acid. After lyophilization, the SLI recovered from the pancreatic perfusate and from antral, fundic, and pancreatic plasma was eluted from Biogel P-10 columns at pH 8.8 as a single immunoreactive peak in approximately the same position as synthetic somatostatin (Fig. 6) . The SLI Comparison of immunologic properties. Serial dilutions of SLI isolated from the pancreatic vein, the gastroepiploic vein and from pancreatic perfusate were proportional and their dilution slopes were parallel to those of synthetic somatostatin in plasma-free buffer (Fig. 7) . (22) and that of Arimura (33) the binding capacity of dog plasma for exogenous somatostatin is <5 ng of somatostatin per ml of plasma, suggesting that infusion of somatostatin at pharmacological doses may saturate the binding proteins and result in circulation of unbound somatostatin. The behavior of somatostatin in plasma is analogous to that of the somatomedins, which also show pH-dependent binding to proteins in human plasma (34) . The inability of immobilized antibodies directed against the NH2-terminal antigenic site of the somatostatin molecule to remove from plasma either endogenous SLI or synthetic somatostatin added to plasma suggests that they both circulate bound to plasma components in a manner that renders the NH2-terminal residues of the molecule inaccessible to such antibodies. This conclusion is supported by the lack of binding to plasma components of the NH,-terminally modified somatostatin analogue, 1251I-labeled Tyr'-somatostatin, in contrast to COOH-terminally modified analogue Tyr"'-somatostatin. It has been proposed (35) that the somatostatin molecule consists of an elongated "hairpin" loop containing a hydrophobic domain at one end of the molecule, and a hydrophilic domain, associated with the disulfide link and the NH2-terminal residues, at the other end. The present study suggests that the NH-terminal region of somatostatin is involved in the binding to plasma components. The contribution of the disulfide linkage of somatostatin to the binding to plasma components was not assessed in this study. Similarly, the study indicates that in radioimmunoassays of canine plasma there will not be competition for the radio-labeled tracer, 125I-Tyrl-somatostatin, between the binding components and an antisomatostatin serum directed against the central portion of the somatostatin molecule, whereas the binding components may significantly interfere in the reaction of somatostatin and radio-labeled tracer with an NH2-terminally directed antisomatostatin serum.
Finally, it should be emphasized that these studies do not resolve the question of the physiologic role or roles, if any, of circulating SLI. Similarity in the molecular size, charge, and immunologic characteristics of plasma SLI and biologically active synthetic somatostatini does not constitute proof of their identity. But even if they should be identical, proof that circulating SLI necessarily has a physiological role would require demonstration that biologically active somatostatin bound to plasma components is available to target receptors.
